# A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects

> **NCT00823940** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 42 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK1362885
- **DRUG:** GSK1362885
- **DRUG:** Glucagon
- **DRUG:** Glucagon + GSK1362885

## Key facts

- **NCT ID:** NCT00823940
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-13
- **Primary completion:** 2009-04-27
- **Final completion:** 2009-04-27
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00823940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00823940, "A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00823940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*